TVGN vs. PAHC, ELVN, COLL, ZYME, NTLA, COGT, PHVS, PSTX, RCKT, and AVBP
Should you be buying Tevogen Bio stock or one of its competitors? The main competitors of Tevogen Bio include Phibro Animal Health (PAHC), Enliven Therapeutics (ELVN), Collegium Pharmaceutical (COLL), Zymeworks (ZYME), Intellia Therapeutics (NTLA), Cogent Biosciences (COGT), Pharvaris (PHVS), Poseida Therapeutics (PSTX), Rocket Pharmaceuticals (RCKT), and ArriVent BioPharma (AVBP). These companies are all part of the "pharmaceutical products" industry.
Tevogen Bio vs.
Phibro Animal Health (NASDAQ:PAHC) and Tevogen Bio (NASDAQ:TVGN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.
In the previous week, Phibro Animal Health had 6 more articles in the media than Tevogen Bio. MarketBeat recorded 10 mentions for Phibro Animal Health and 4 mentions for Tevogen Bio. Phibro Animal Health's average media sentiment score of 0.88 beat Tevogen Bio's score of 0.37 indicating that Phibro Animal Health is being referred to more favorably in the media.
Phibro Animal Health has a net margin of 1.75% compared to Tevogen Bio's net margin of 0.00%. Phibro Animal Health's return on equity of 25.35% beat Tevogen Bio's return on equity.
Phibro Animal Health has higher revenue and earnings than Tevogen Bio.
Phibro Animal Health has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Comparatively, Tevogen Bio has a beta of -1.14, suggesting that its share price is 214% less volatile than the S&P 500.
Phibro Animal Health presently has a consensus price target of $21.00, suggesting a potential downside of 6.67%. Tevogen Bio has a consensus price target of $4.20, suggesting a potential upside of 196.82%. Given Tevogen Bio's stronger consensus rating and higher probable upside, analysts plainly believe Tevogen Bio is more favorable than Phibro Animal Health.
Phibro Animal Health received 314 more outperform votes than Tevogen Bio when rated by MarketBeat users. However, 100.00% of users gave Tevogen Bio an outperform vote while only 60.11% of users gave Phibro Animal Health an outperform vote.
99.3% of Phibro Animal Health shares are owned by institutional investors. 50.1% of Phibro Animal Health shares are owned by company insiders. Comparatively, 56.6% of Tevogen Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Phibro Animal Health beats Tevogen Bio on 9 of the 15 factors compared between the two stocks.
Get Tevogen Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for TVGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tevogen Bio Competitors List
Related Companies and Tools
This page (NASDAQ:TVGN) was last updated on 2/22/2025 by MarketBeat.com Staff
